Loading asset research
Annovis Bio Inc. Common Stock
ANVSNYSE · USD · StocksQuote as of · Exchange session not verified$1.12
-5.88%
Today
ANVS
Loading 1D prices…
Market cap
$47.7M
Volume
1.9M
52w high
$5.5052w low
$1.10Company profile
Annovis Bio Inc. Common Stock
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
NYSE
Display currency
USD
Location
Malvern, PA, United States
Employees
7
Fiscal year end
1231
CIK
1477845
Session & valuation
Open$1.20
Previous close$1.19
Day high$1.23
Day low$1.10
30-day avg. volume966.9K
Outstanding shares42.6M
Diluted EPS-$1.40
Latest annual period
P/E (trailing)-0.80
P/E (forward)-1.30
Price / book-11.20
Beta1.24
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| HOWLWerewolf Therapeutics Inc. Common Stock | $47.7M | $0.00 | — | -$1.33 | -0.82% | Buy |
| SCYXSCYNEXIS Inc. Common Stock | $48.2M | $20.6M | -41.79% | -$0.17 | +2.98% | Buy |
| GRCEGrace Therapeutics Inc. Common Stock | $46.7M | $0.00 | — | -$0.47 | -1.77% | Buy |
| IBOImpact BioMedical Inc. Common Stock | $49.6M | $32K | -36993.75% | -$0.38 | +4.31% | Unrated |
| CLNNClene Inc. Common Stock | $45.9M | $200K | -13086.50% | -$2.65 | -2.19% | Buy |